Related Experiment Video
Updated: Jun 6, 2026

A 3D Organotypic Melanoma Spheroid Skin Model
Published on: May 18, 2018
Advances in targeted therapy for melanoma
Philip Friedlander1, F Stephen Hodi
1Instructor of Medicine, Department of Medical Oncology at Dana Farber Cancer Institute in Boston, Massachusetts 02115, USA. pfriedlander@partners.org
Abstract:
Metastatic melanoma remains an aggressive malignancy conferring a very poor prognosis, and standard chemotherapeutic and immunologic treatments have not demonstrated an overall survival benefit. No molecularly targeted therapy is approved for the treatment of advanced melanoma. Melanoma is a molecularly heterogeneous malignancy, and optimal treatment in a given patient is likely to depend on the presence of specific molecular abnormalities. Aberrations in components of signal transduction pathways have been identified that modulate melanoma proliferation and survival. Mutations that activate the mitogen activated protein kinase (MAPK) pathway via BRAF or NRAS are present in the majority of melanomas arising on skin intermittently exposed to the sun. Mutations that activate the KIT oncogene are more commonly present in melanomas arising from mucosal, acral, or chronic sun-damaged sites. Inhibitors of the MAPK pathway and of KIT are currently undergoing clinical investigation. In this article, we review advances in targeted strategies to treat different subgroups of patients with melanoma.
Insights
Metastatic melanoma is aggressive, with limited treatment options. Targeted therapies focusing on specific molecular abnormalities, like BRAF, NRAS, or KIT mutations, show promise for improving patient survival.
Area of Science:
- Oncology
- Molecular Biology
- Dermatology
Background:
- Metastatic melanoma is an aggressive cancer with a poor prognosis.
- Current standard treatments offer limited survival benefits.
- No targeted therapies are approved for advanced melanoma.
Purpose of the Study:
- To review advances in targeted treatment strategies for melanoma subgroups.
- To highlight the role of molecular abnormalities in melanoma progression.
- To discuss the potential of pathway-specific inhibitors.
Main Methods:
- Review of current literature on melanoma molecular alterations.
- Analysis of signal transduction pathways involved in melanoma.
- Discussion of clinical investigations for targeted therapies.
Main Results:
- Specific mutations (BRAF, NRAS, KIT) are identified in melanoma subgroups.
- Mitogen-activated protein kinase (MAPK) pathway mutations are common.
- KIT oncogene mutations are prevalent in specific melanoma types.
Conclusions:
- Targeted therapies inhibiting MAPK pathway or KIT are under investigation.
- Personalized treatment based on molecular profiles is crucial.
- Advances in targeted strategies offer hope for advanced melanoma patients.
More Related Videos
Related Concept Videos
Targeted Cancer Therapies
There are several types of targeted therapies against specific...
Targeted Cancer Therapies
There are several types of targeted therapies against specific...
Tumor Immunotherapy
Skin Cancer
Basal Cell Carcinoma (BCC): BCC is the most common type of skin cancer, accounting for about 80% of cases. It typically develops in...
Combination Therapies and Personalized Medicine
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
Modified-Release Drug Delivery Systems: Site-Targeted

